ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ibutamoren

Also written as “LUM-201” and “MK0677”.

Its studies are mostly in Dwarfism, Pituitary · Obesity · Hip Fractures · Alzheimer Disease, led by 2 companies.

Drug pageIbutamoren: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 21, 20259 company-led studies, 5 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lumos Pharma75 open or runningphase 3since Apr 21, 2025Oct 26, 2020Dec 2027phase 3 · NCT06948214
Merckits history only20 open or runningphase 2since Dec 15, 2003Dec 15, 2003none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Lumos Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 26, 2020First study: phase 2 study in Dwarfism, PituitaryFirst studyNCT04614337 · 104 enrolled · United States, Australia, Israel and more
  2. Mar 17, 2021Phase 2 study in Dwarfism, PituitaryNCT04806854 · 24 enrolled · Chile
  3. Feb 10, 2022Phase 2 study in Dwarfism, PituitaryNCT05250063 · 15 enrolled · United States, Poland
  4. Mar 19, 2023Phase 2 study in Dwarfism, PituitaryNCT05796440 · 60 planned · United States, Australia
  5. Apr 21, 2025Phase 3 study in Dwarfism, PituitaryNCT06948214 · 150 planned · United States, Argentina, Australia and more
  6. Aug 5, 2025Phase 3 study in Dwarfism, PituitaryNCT07129759 · 150 planned
  7. Jul 9, 2026Phase 2 study in ObesityNCT07754045 · 202 planned

Ahead

  1. Dec 2027Primary completion: phase 3 study in Dwarfism, PituitaryNCT06948214
  2. Feb 15, 2028Primary completion: phase 2 study in ObesityNCT07754045
  3. Mar 2028Primary completion: phase 2 study in Dwarfism, PituitaryNCT05796440
  4. Feb 2030Primary completion: phase 3 study in Dwarfism, PituitaryNCT07129759

TargetBeta

GHSR →read by rule
“Ghrelin receptor agonist”ChEMBL 37, by rule

Studies

All 7 Lumos Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07754045Obesity2Not yet recruitingFeb 15, 2028202
NCT07129759Dwarfism, Pituitary3Not yet recruitingFeb 2030150
NCT06948214Dwarfism, Pituitary · United States, Argentina, Australia and more3RecruitingDec 2027150
NCT05796440Dwarfism, Pituitary · United States, Australia2By invitationMar 202860
NCT05250063Dwarfism, Pituitary · United States, Poland2CompletedJan 22, 202515
NCT04806854Dwarfism, Pituitary · Chile2Active, not recruitingApr 203024
NCT04614337Dwarfism, Pituitary · United States, Australia, Israel and more2CompletedSep 4, 2024104

How it is read

Names in the registry

  • “LUM-201”, 7 entries
  • “MK0677”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.